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Abstract
Objective: To assess the impact of instructional guidance in the regular use of use nicotine nasal spray
(NNS) on the true use of NNS during the first three weeks of smoking cessation for heavy smokers who
are willing to quit.
Methods: This randomized, open, controlled trial included 50 patients who were heavy smokers, were
willing to quit, and attending an academic outpatient clinic in Western Switzerland. Patients were
randomised to instruction on NNS use as "ad libitum" (administration whenever cravings appear; control
group) or to use NNS when craving appears and at least every hour when awake (intervention group).
Intakes were monitored using an electronic device fixed in the spray unit (MDILog™) during the first three
weeks of use. Self reported abstinence from smoking at six months was confirmed by expired-air carbon
monoxide. Using intention-to-treat analysis, random-effect GLS regression was used to calculate the mean
difference of daily doses between groups controlling for lack of independence between measures from the
same individual.
Results: One patient was lost to follow-up. At baseline randomization, the group receiving instruction to
use NNS hourly included more women, patients with previous desires to quit, and patients with more
psychiatric comorbidities and less somatic complaints compared to the group instructed to use NNS with
cravings (group imbalance). Both groups self-administered more than the daily recommended dosage of 8
uses. Mean daily usage was 13.6 dose/day and 11.1 dose/day for the group instructed to use NNS hourly
and with cravings, respectively. Adjusting for baseline imbalance, the increased daily doses in the
intervention group (hourly use) remained nonsignificant compared to ad libitum use (-0.5 dose/day; CI 95%
-6.2; 5.3, from day 1 to day 7; and 2.3 dose/day; CI 95% -5.4; 10.0, from day 8 to day 21). Instructing patients
to use the NNS daily had no effect on smoking cessation at six months (RR = 0.69; CI 95% 0.34; 1.39).
Conclusion: Heavy smokers willing to quit use NNS frequently, regardless of the instructions given.
Recommending the use of NNS only when craving appears for heavy smokers willing to quit seems
acceptable compared to prescribing hourly administration.
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Background
Cigarette smoking is currently the greatest preventable
cause of death in our society; smoking cessation is
regarded as one of the important preventive practices in
modern medicine [1]. Use of nicotine replacement prod-
ucts increases the rate of smoking cessation 1.5 to 2 fold
[2]. Nevertheless, there is uncertainty about the relation-
ship between dose of replacement products, pattern of
use, and success rate. Regarding the use of nicotine gum,
improved outcome is reported with fixed dose rather than
ad libitum usage [3]. Increasing the dose of nicotine
replacement therapy has been shown to increase success
rate [4]. Nicotine nasal spray (NNS) was developed to
allow rapid delivery of nicotine through the nasal
mucosa, allowing more rapid absorption than with the
nicotine patch or gum. This rapid absorption and the
user's ability to control the rate of use with NNS allow
subjects to adjust the dose as needed. This type of nicotine
substitution is particularly suitable for highly dependent
smokers [5], willing to quit but with acute episodes of
craving [6]. Different patterns of use have been observed
between successful quitters and failures; successful quit-
ters reportedly use higher doses [7]. Prescribing regularly
scheduled use of NNS rather than instructing the patient
to use the spray only when desired may improve the
number of successful quitters. However, little is known
regarding the response of patients to instructions for reg-
ular, scheduled use of nicotine substitutes. The aim of our
study is to assess the effect of instructions for regular use
of NNS on the true use of NNS during the first three weeks
of attempted quitting; a secondary aim is to assess the
effect of instruction for regular NNS use on smoking ces-
sation success rates at 6 months compared with the cur-
rently recommended "ad libitum" use.
Methods
Participants
This open, randomized, controlled study was conducted
in a group of 50 highly dependent smokers seen in the
Department of Ambulatory care and Community Medi-
cine in Lausanne, Switzerland. Patients were defined as
highly dependent using Fagerstrom's criteria modified by
Heatherton and al (smoking ≥ 20 cigarettes/day and/or
smoking the first cigarette within 30 minutes after wak-
ing) [8]. To be included, patients had to be in the stage of
preparation according to Prochaska and Di Clemente's
stages of change model [9]. Exclusion criteria were a his-
tory of myocardial infarction in the preceding 3 months,
pregnancy or breast-feeding, and use of any form of
smokeless tobacco or other nicotine replacement therapy.
At inclusion, demographic characteristics, smoking his-
tory, and nicotine dependence were recorded, and partic-
ipants were asked about their smoking habits, prior quit
attempts, current or prior psychiatric treatment, and moti-
vation to quit. Subjects gave written informed consent to
participate in the trial. The participants received advice to
stop smoking completely at a fixed quit date. They were
instructed how to use the NNS to enhance its acceptability
and reduce local adverse effects.
Randomization, allocation, blinding
Prior to data collection, a pharmacist prepared a randomi-
zation list of 50 blinded shuffled paper slips including 25
As and 25 Bs which were used to assign patients to treat-
ment groups. Each paper slip was sealed in an opaque
numbered envelope. Once a patient was included in the
study and baseline data was collected, the sealed envelope
was opened by the investigator to reveal the patient's allo-
cation. Patients were blinded to the other intervention but
were aware of their own. Investigator could not be
blinded, as he was to give instructions on the use of NNS.
During follow-up, the research nurse was not expressively
made aware of the allocation but made all patients aware
of the importance of using the spray when craving
appeared. Statistician was blinded to which group
received which intervention until the end of the analysis.
Intervention
During the first month, subjects in the intervention group
received instruction from the physician to use NNS when
craving appears and at least 2 puffs/hour, for an average of
1 mg nicotine/hour when awake. Instructions were given
to the patient as if this was the usual way of using the
NNS.
Control
In the control group, participants were instructed to use
NNS as needed to suppress withdrawal symptoms when
cravings appeared.
In both groups, 1) the use of NNS was free during the first
two months, 2) during follow-up, physicians were trained
to advise patients who experience craving to use the spray
more often, 3) after one month, participants were advised
to reduce the use of NNS if tolerable.
Outcomes
During the first month, the number of puffs was recorded
with an electronic device fixed on the spray unit (micros-
witch-actuated metered-dose inhaler chronology,
MDILog™, model MDC-511, Medtrac, Denver, Colorado
USA). The MDILog™ recorded the date and time of each
activation. Only full days were taken into consideration;
this means that the first day of use was not monitored.
Doses are defined as grouped puffs that are spaced less
than one minute apart. A series was defined as a sequence
of puffs separated by more than one second but less than
one minute. The normal number of puffs per dose should
be two. Puffs that were monitored at the same second
were counted as single.Substance Abuse Treatment, Prevention, and Policy 2009, 4:12 http://www.substanceabusepolicy.com/content/4/1/12
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Participants were informed of the aim of the MDILog™,
but they did not see the results. Because the MDILog™ sys-
tem showed variable reliability in previous studies [7], we
followed a precise validation protocol to ensure data qual-
ity. Participants were asked to return their MDILog™ and
all bottles of nicotine (empty, started, or full) at each visit.
The research nurse checked every MDILog™ thoroughly
with a software program and compared the total record of
puffs since the last visit with the weight of the returned
nasal spray bottles. If any technical deficiency or record
discrepancy was detected, the MDILog™ was changed.
Patients were monitored during the first month of use (a
total of 27 to 35 days). Five patients had missing data
completely at random due to the MDILog™'s initial tech-
nical failures. The trial steering committee therefore
decided to extract data from the 21st full days of use
instead of the initial 28 that were planned. All patients
were instructed to administer two puffs for every dose.
Data was collected to evaluate the number of series that
had more or less than two puffs.
The criterion of abstinence was self-reported continuous
abstinence from smoking from the beginning of the sub-
stitution to the end of the 6th month of follow-up, vali-
dated by an expired-air carbon monoxide (CO)
concentration of less than 10 parts per million (ppm) at
all visits (Bedfont Smokerlyzer, Bedfont Scientific Ltd.,
Rochester, UK). "Occasional slips" (i.e. less than 1 ciga-
rette/day during the examined period) were tolerated.
Smoking cessation was defined as successful in patients
with smoking abstinence or "occasional slips" with a CO
rate ≤ 10 ppm.
Follow-up visits were scheduled at 1 and 2 weeks and at 1,
2, 3, and 6 months. At each follow-up visit, participants
were asked about cigarette consumption during the last 24
hours, smoking since last visit, and average number of
puffs of NNS daily.
Statistical analysis
The number of daily intakes was measured for each sub-
ject from both groups during the initial 21 days of moni-
toring (D+1 to D+22). Differences of daily intake between
groups were computed using random-effect generalised
least square regression (GLS) to take into account the lack
of independence between measurements from the same
participants. Interclass correlation coefficients were
reported to estimate the proportion of variance related to
individual characteristics. The analysis was stratified by
week to see if differences between groups were constant
through time and by weekdays. If important group imbal-
ance was observed (>20% relative difference between
groups), these factors were to be included secondarily in
the regression analysis for adjustment.
Proportion of success were calculated for each group at 1
week, 2 weeks, 1 month, 2 months, 3 months, and 6
months with a 95% confidence interval (CI 95%). Rela-
tive risk (RR) of success at six months between groups was
computed with CI 95%. P value was given for chances of
a RR of 1 (chances that the intervention has the same
effect as the control on smoking cessation).
Sample size was calculated for the primary objective only.
Using data from a previous study [7], the expected average
number of daily puffs (2 puffs = 1 dose) is expected to be
9 with a standard deviation (SD) of 8. The sample size was
calculated to detect an increase up to 16 daily puffs (8
doses) with a significance level set at 0.05 and a power of
0.8. Each group was to include 21 participants. Expecting
dropouts, the number of patients to be included was
rounded to 25 per group. All calculations were performed
with StataCorp. 2008 Statistical Software, Release 10.0
(College Station, Texas: Stata Corporation).
The study was approved by the ethical review committee
for clinical research of the Department of Internal Medi-
cine, University of Lausanne (Prot 29/99).
Results
Data was collected from June 2000 to December 2001. As
planned, 25 patients were included in each group. Four
patients (two from each group) did not use their NNS
from the second day on; two because of the side effects
occurring at the testing session and two because they did
not feel ready to quit smoking. These patients were
included in the intention to treat analysis. One participant
from the intervention group moved away and was lost to
follow-up after his encounter at three months (Figure 1).
Balance between groups was not achieved (Table 1). The
intervention group included more females (40% vs.
16%), participants who had fewer previous attempts to
quit smoking (2.2 vs. 3.1), had more co-occurring psychi-
atric disorders (44% vs. 24%), and fewer somatic com-
plaints (56% vs. 70.1%) than the control group (Table 1).
NNS were used similarly between patients from both
groups with important variances; these differences were
due to individual characteristics rather than the interven-
tion (Table 2). The calculated total number of 0.5 mg
puffs highly correlated with the weighed consumption of
NNS (r = 0.947; p < 0.001). After their physician visit,
patients who were counselled to use the NNS hourly used
the NNS an average of 13.6 times a day whereas those
instructed to use it when cravings appeared used the NNS
an average of 11.1 times per day; Figure 2 shows mean
daily use of NNS. Patients told to use the NNS once every
hour, 12 times a day, used an average 2.6 (CI95% -2.7;
7.9) more doses every day compared to those told to useSubstance Abuse Treatment, Prevention, and Policy 2009, 4:12 http://www.substanceabusepolicy.com/content/4/1/12
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the NNS when craving appeared; this difference was non
significant. The fraction of variance due to individual
characteristics other than of the prescribed intervention
(instructed use of NNS) was 0.606. The difference in the
number of daily doses between groups was less important
during the first week (0.8; CI 95% -5.1; 6.7) than during
the second (4.0; CI 95% -1.9; 9.9) and third week (3.0; CI
95% -2.5; 8.5). Including the patient's daily number of
smoked cigarettes in the regression model did not
improve the likelihood ratio of the model to predict the
daily dose intake of NNS; the observed variance between
patients cannot be explained by the patient's frequency of
smoking before cessation.
Adjusting for group imbalance (sex, psychiatric comor-
bidities, number of previous desires to quit) and stratify-
ing the analysis between day 1 to 7 and day 8 to 21, the
observed increase in the number of daily doses was -0.5
(CI95% -6.2; 5.3) from day 1 to 7 and 2.3 (CI95% -5.4;
10.0) from day 8 to day 21.
The proportion of abstinent patients over time is shown
in Figure 3. A total of 8 of 24 patients in the intervention
arm and 12 of 25 patients in the control group success-
fully stopped smoking at 6 month follow up. Patients
receiving instruction to use NNS once per hour had a
lower cessation rate compared to those instructed to use
Flow Chart Figure 1
Flow Chart.
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the NNS when cravings appeared (relative risk of 0.69,
CI95% 0.34; 1.39) although the difference was not signif-
icant (Fisher's exact test, p = 0.296). Eleven patients who
had not ceased smoking reported a reduction in cigarette
consumption (five in the intervention group and six from
the control group). However, at six months only one
patient smoked less than 50% of the initial amount while
continuing to use the NNS.
Discussion
This negative study shows that differences in NNS intake
are more dependent on individual characteristics than on
the recommended frequency of use. We observed frequent
use of nasal spray in both groups. Average use was 13.6
intakes/day and 11.1 intakes/day in groups instructed to
use NNS hourly versus with cravings, respectively. Nico-
tine doses were higher in both groups than those recom-
mended by the manufacturer (8 daily intakes) and
observed by Mabry et al [10]. Physicians were trained to
follow patients and encourage them to use the NNS as
much as possible to prevent craving and relapse. Further-
more, patients were all heavy smokers willing to quit,
which could explain their regular use of the NNS inde-
pendently of the given recommendation. Even if a slight
trend towards more regular use in patients instructed to
use the NNS hourly was observed, the minimal inferred
average intake for the control group is clinically sufficient
to justify the actual recommendation to use the substitute
when craving appears. Seeing the patients regularly during
the first two months could help increase compliance with
the recommended use of NNS. We observed in both
groups an increased use after visits with physicians. Feel-
ings of empathy, encouragement in their initiative, and
receiving counselling could help improve the regular use
of NNS. Finally, differences exist in the use of NNS
between individual patients. These differences were how-
ever not explained by the type of instructions given nor by
previous smoking habits.
The proportion of success at 6 months (41%) in our study
was slightly superior to rates seen in other studies using
NNS, with reports varying between 10 and 35% at 6
months [5-7,11-14]. In our study, patients were followed
regularly and counselling was offered to support their
effort. Counselling and support might have increased use
of the NNS, which in turn could have helped them in
remaining abstinent [15]. Furthermore, positive instruc-
tions on the regular use of NNS given by physicians could
have also helped in both groups by increasing expecta-
tions, which are known to have an important placebo
Table 1: Patients' baseline characteristics.
NNS
1 dose per hour/12 h a day
NNS
Dose when cravings appear (control)
n = 25 n = 25
Age
Mean (SD) 40.2 (11.4) 40.8 (10.1)
Sex
% male* 60% 84%
Education
% high school/university 52% 58.3%
Health
Psychiatric comorbidities* 44% 24%
Smoking habits
Daily intake; mean cig/day (SD) 29.8 (11.4) 30 (10.3)
Baseline CO (ppm); mean (SD) 42.0 (16.1) 40.9 (19.0)
Years of consumption; mean (SD) 18.9 (11.0) 21.0 (9.0)
Previous attempts; mean (SD)* 2.2 (1.7) 3.1 (3.1)
*Over 20% relative difference between groups.
Cig: cigarettes; CO: carbon monoxide; SD: standard deviation.
Mean number of intakes taken daily for patients told to use  NNS at least once every hour and for those told to use NSS  every time cravings appear Figure 2
Mean number of intakes taken daily for patients told 
to use NNS at least once every hour and for those 
told to use NSS every time cravings appear.
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effect [16]. A small risk of addiction to the NNS, due to the
rapid absorption and high peak level, has been previously
described [5,12]. However, the main reason for a pro-
longed use, as suggested by Hughes, is the fact that highly
dependent smokers need a long transition period to
recover from their physiological dependency [17,18]. In
our study, only 1 patient among 50 was still using the
NNS at six months. He was also the only patient who was
smoking less than 50% of the initial amount after 6
months; all other patients who had reduced their con-
sumption relapsed. This suggests that temporary reduc-
tion is probably real (no compensatory smoking) but not
appropriate in the long term for highly dependent smok-
ers [19].
To our knowledge, this is the second study where smokers
have been instructed to use the NNS regularly and not on
an "ad libitum" basis. As in our study, Tonnesen et al [14]
did not observe a difference in the rate of success between
smokers instructed to use the NNS regularly or on
demand. Mooney et al [20] did not observe any improve-
ment in the cessation rate at six months when encourag-
ing use of nicotine gum with psychological interventions
(brief feedbacks or contingency management). Neverthe-
less, in a large randomized trial, Shiffmann et al's observa-
tions support the theory of a causal relationship between
higher use of nicotine substitute and success [4]. It there-
fore seems reasonable to believe that patient's use of sub-
stitutes depend more of their own reticence [21] or
motivations [17] rather than instructions given by their
practitioner.
The strength of this study is the precision in the measures
of individual daily use of NNS using the MDILog™ and
measuring effects of instructions in a pragmatic approach.
The major limitation is the low power of this study. The
small sample size resulted in clinical significant group
imbalance for gender, co-occurring psychiatric disorders,
and number of previous desires to quit. Nevertheless, con-
trolling for imbalance in the regression analysis did not
modify results. Our observations are limited to the use of
the spray during the first month whereas most patients
used the NNS for much longer. It cannot be excluded that
Smoking abstinence during the 6 month follow-up (25  patients in each group) Figure 3
Smoking abstinence during the 6 month follow-up 
(25 patients in each group). One patient in the interven-
tion group was lost to follow-up after the 3 month visit.
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Table 2: NNS use during the first 21 full days of treatment; data from 1050 days of observation from 50 patients.*
NNS
1 dose per hour
NNS
Ad libitum
Wald Chi2 test ICC‡
Mean (CI 95%) Mean (CI 95%) p-value ρ
Doses
Daily number of intakes 13.6 (4.7; 22.6) 11.1 (7.3; 14.8) p = 0.332 ρ = 0.606
Daily number of correct doses (2 puffs) 12.0 (3.9; 20.2) 9.3 (5.9; 12.7) p = 0.263 ρ = 0.593
Daily number of single puff 0.5 (-0.4; 1.5) 0.8 (0.4; 1.2) p = 0.470 ρ = 0.414
Daily number of doses over 2 puffs 1.1 (-0.1; 2.2) 1.0 (0.5;1.4) p = 0.780 ρ = 0.331
Period of use
Daily intake 1st week 13.7 (3.6; 23.8) 12.9 (8.7; 17.1) p = 0.788 ρ = 0.798
Daily intake 2nd week 14.5 (4.4;24.6) 10.5 (6.3; 14.7) p = 0.184 ρ = 0.696
Daily intake 3rd week 12.8 (5.6; 22.2) 9.8 (5.8;13.7) p = 0.287 ρ = 0.656
Week days
Daily intake weekends 13.2 (4.3; 22.2) 9.7 (6.0;13.4) p = 0.189 ρ = 0.525
Daily intake weekdays 13.8 (4.5; 23.1) 11.6 (7.7; 15.4) p = 0.419 ρ = 0.652
Use of NNS
Days NNS was used† 22.9 (19.0; 27.3) 23.0 (18.8;27.3) p = 0.966 -
Total nicotine (mg)† 418 (294; 543) 296 (188; 405) p = 0.131 -
* Results are drawn from random-effect GLS regression taking lack of independence from measurements from the same patients into 
consideration.
† Individual level data was used for this analysis. T-test was used to calculate p-value.
‡ The Intraclass Correlation Coefficient (ρ) corresponds to the percentage of variance due to individual characteristics (cluster level).Substance Abuse Treatment, Prevention, and Policy 2009, 4:12 http://www.substanceabusepolicy.com/content/4/1/12
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the spray was used differently between groups after mon-
itoring ended. This however had apparently no effect on
the rate of success at six months. Finally, our observations
concern heavy smokers willing to quit. Use of the NNS
could differ for other levels of dependence or for smokers
who are not willing to quit.
Conclusion
Heavy smokers willing to quit use NNS in high doses,
whatever the instructions given. Recommending the use
of spray when craving appears is acceptable compared to
prescribing fixed regular doses. For heavy dependant
smokers willing to quit, when insisting on the use of NNS
when craving appears, it does not seem to matter what
instructions are given on the minimal recommended daily
administration.
Abbreviations
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